DNMT3A and leukemia: Building upon this study, Shlush et al. demonstrated the persistence of DNMT3A mutations in HSCs of patients with AML whose blasts expressed both DNMT3A and NPM1 mutations, suggesting that preleukemic clones undergo stepwise acquisition of genetic lesions as they develop into leukemia (3).